TWI349557B - Use of hpv 16 and hpv 18 vlps for vaccine preparation - Google Patents

Use of hpv 16 and hpv 18 vlps for vaccine preparation

Info

Publication number
TWI349557B
TWI349557B TW092135963A TW92135963A TWI349557B TW I349557 B TWI349557 B TW I349557B TW 092135963 A TW092135963 A TW 092135963A TW 92135963 A TW92135963 A TW 92135963A TW I349557 B TWI349557 B TW I349557B
Authority
TW
Taiwan
Prior art keywords
hpv
vlps
vaccine preparation
vaccine
preparation
Prior art date
Application number
TW092135963A
Other languages
English (en)
Chinese (zh)
Other versions
TW200423957A (en
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200423957A publication Critical patent/TW200423957A/zh
Application granted granted Critical
Publication of TWI349557B publication Critical patent/TWI349557B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW092135963A 2002-12-20 2003-12-18 Use of hpv 16 and hpv 18 vlps for vaccine preparation TWI349557B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (2)

Publication Number Publication Date
TW200423957A TW200423957A (en) 2004-11-16
TWI349557B true TWI349557B (en) 2011-10-01

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092135963A TWI349557B (en) 2002-12-20 2003-12-18 Use of hpv 16 and hpv 18 vlps for vaccine preparation

Country Status (28)

Country Link
US (2) US20060251676A1 (OSRAM)
EP (1) EP1572233B1 (OSRAM)
JP (1) JP5475939B2 (OSRAM)
KR (3) KR101361769B1 (OSRAM)
AP (1) AP2005003347A0 (OSRAM)
AR (1) AR042530A1 (OSRAM)
AT (1) ATE503492T1 (OSRAM)
AU (1) AU2003293942B2 (OSRAM)
BE (3) BE2015C068I2 (OSRAM)
BR (1) BR0317544A (OSRAM)
CA (1) CA2510457C (OSRAM)
CY (1) CY1111552T1 (OSRAM)
DE (1) DE60336581D1 (OSRAM)
DK (1) DK1572233T3 (OSRAM)
EA (2) EA009179B1 (OSRAM)
EC (1) ECSP055869A (OSRAM)
IL (1) IL169085A (OSRAM)
IS (1) IS2811B (OSRAM)
MA (1) MA27581A1 (OSRAM)
MX (1) MXPA05006764A (OSRAM)
MY (1) MY144492A (OSRAM)
NO (1) NO20052846L (OSRAM)
NZ (1) NZ540811A (OSRAM)
OA (1) OA13147A (OSRAM)
PL (1) PL215257B1 (OSRAM)
PT (1) PT1572233E (OSRAM)
TW (1) TWI349557B (OSRAM)
WO (1) WO2004056389A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1877086A2 (en) * 2005-04-26 2008-01-16 GlaxoSmithKline Biologicals SA Vaccine
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
EP2154147B1 (en) * 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
AU2009348078B2 (en) * 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
WO2015114506A2 (en) 2014-01-31 2015-08-06 Marini Bruna Biosensor for the determination of infections and associated pathologies
AU2015335652B2 (en) 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
AU2016273638B2 (en) * 2015-06-02 2019-06-06 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
AU2019231654B2 (en) * 2018-03-06 2025-12-11 Precigen, Inc. Human papillomavirus vaccines and uses of the same
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
CN110551182A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DE69835294T2 (de) 1997-09-05 2007-07-26 Medimmune, Inc. Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
PT1150712E (pt) * 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법

Also Published As

Publication number Publication date
MY144492A (en) 2011-09-30
ATE503492T1 (de) 2011-04-15
EA200500834A1 (ru) 2006-02-24
PL215257B1 (pl) 2013-11-29
JP2006512413A (ja) 2006-04-13
BE2015C067I2 (OSRAM) 2024-08-08
PL377710A1 (pl) 2006-02-06
KR20050086924A (ko) 2005-08-30
KR20120123616A (ko) 2012-11-08
KR101361769B1 (ko) 2014-02-10
BE2015C069I2 (OSRAM) 2024-08-08
AR042530A1 (es) 2005-06-22
HK1085378A1 (en) 2006-08-25
DK1572233T3 (da) 2011-06-27
JP5475939B2 (ja) 2014-04-16
TW200423957A (en) 2004-11-16
DE60336581D1 (de) 2011-05-12
EA009179B1 (ru) 2007-12-28
EP1572233A1 (en) 2005-09-14
ECSP055869A (es) 2005-09-20
AU2003293942A1 (en) 2004-07-14
PT1572233E (pt) 2011-06-07
US20060251676A1 (en) 2006-11-09
AP2005003347A0 (en) 2005-06-30
CA2510457C (en) 2011-12-06
EA200701633A1 (ru) 2007-12-28
BR0317544A (pt) 2005-11-22
IL169085A0 (en) 2007-07-04
IS7885A (is) 2005-06-09
MXPA05006764A (es) 2005-09-08
IS2811B (is) 2012-11-15
KR20120118087A (ko) 2012-10-25
WO2004056389A1 (en) 2004-07-08
CY1111552T1 (el) 2015-08-05
NZ540811A (en) 2007-03-30
NO20052846L (no) 2005-07-13
BE2015C068I2 (OSRAM) 2024-08-08
CA2510457A1 (en) 2004-07-08
US20050287161A1 (en) 2005-12-29
AU2003293942B2 (en) 2009-12-10
IL169085A (en) 2014-04-30
OA13147A (en) 2006-12-13
MA27581A1 (fr) 2005-10-03
EP1572233B1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
IL163814A0 (en) Virus-like particles of human papillomavirus
ZA200502618B (en) Human papillomavirus polypeptides and immunogenic compositions
IL158107A0 (en) Human papillomaviruses vaccine
HUP0204250A3 (en) Use of hiv-protein or -polynucleotide for vaccine produce
AU2003227533A8 (en) Virus like particle from papillomavirus and their use in vaccine
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
TWI339662B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
IL162381A0 (en) A recombinant dna construct and a process for the preparation of a non-toxic anthrax vaccine
IL159067A0 (en) METHODS FOR PREPARATION AND USE OF 1alpha,24 (S) -DIHYDROXYVITAMIN D2
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
ZA200601991B (en) Process for the preparation of renzapride and intermediates thereof
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
EP1617810A4 (en) PROCESS FOR THE PREPARATION AND USE OF 1ALPHA, 24 (S) -DIHYDROXYVITAMINE D2
IL174325A0 (en) Dna vaccine compositions and methods of use
GB0200258D0 (en) Detection of human papillomavirus
EP1439845A4 (en) INACTIVATION OF THE PAPILLOMA
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
AU2002356763A1 (en) Use of a technically modified cell as a vaccine for treating tumoral disease
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
AU2002333157A1 (en) Compound for treatment of anxiety and methods of preparation and use thereof
AU2003239773A1 (en) Preparation of vaccines
AU2003281909A1 (en) Method of obtaining conjugate vaccines and vaccine compositions containing same
AU2003249364A8 (en) Algal gdp-mannose-3',5'-epimerases and methods of use thereof
IL166773A0 (en) Pravastatin pharmaceutical formulations and methods of their use

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent